Continuous Microgestin 1/20
Dysmenorrhea
Endeavor HealthPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Dysmenorrhea cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclic Microgestin 1/20 Endeavor Health | Phase 4 | BB |
Naproxen Endeavor Health | Phase 4 | BB |
Same molecule, other indications
Continuous Microgestin 1/20 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →